← All trials
NCT03267589
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 16, 2018
- Primary completion
- Mar 30, 2019
- Completion date
- Sep 30, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 75
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Nordic Society for Gynaecologic OncologyLead sponsor
- European Network for Gynaecological Oncological TrialCollaborator
- Australia New Zealand Gynaecological Oncology GroupCollaborator
- Katholieke Universiteit LeuvenCollaborator
- Cooperative Ovarian Cancer Group for Immunotherapy NetworkCollaborator
- GCIG: Gynecologic Cancer InterGroupCollaborator
- Gynecologic Oncology Trial and Investigation Consortium, JapanCollaborator
- Korean Gynecologic Oncology GroupCollaborator
- North Eastern Germany Society of Gynaecologic OncologyCollaborator
- University of TorontoCollaborator
- Scottish Gynaecological Cancer Study GroupCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.